ArticleJournal of pathology and translational medicine2023
What's new in dermatopathology 2023: WHO 5th edition updates.
Article in Journal of pathology and translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cutaneous Leiomyosarcoma of the Skin: An Updated Review of Epidemiology, Pathogenesis, and Management.International journal of dermatology · 2026Review
- Classification of High- and Low-Risk Patients With Dermal Leiomyosarcoma: An Exploratory Nationwide Cohort Study.Journal of surgical oncology · 2026Article
- Basosquamous Cell Carcinoma: A Summary of the Definitions and Demographic, Clinical, Therapeutic, Histological, and Outcome Analysis of 20 Consecutive Basosquamous Cell Carcinomas in Comparison with 130 Basal Cell and 81 Squamous Cell Carcinomas in a Single Institution.Journal of clinical medicine · 2026Article
- Cutaneous soft tissue tumors in the 5th edition of the World Health Organization classification of skin tumors: key updates and new entities.Journal of pathology and translational medicine · 2026Article
- Translating Features to Findings: Deep Learning for Melanoma Subtype Prediction.Dermatopathology (Basel, Switzerland) · 2025Review
- Prognosis and Follow-Up Recommendations for Subcutaneous and Dermal Leiomyosarcoma: Local Recurrence, Metastasis, and Overall Survival in a Danish Nationwide Cohort of 661 Patients.Journal of surgical oncology · 2025Article
- Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression.Dermatology practical & conceptual · 2025Review
- Review
- Histologic and Immunohistochemical Patterns in Lymphomatoid Papulosis: A Systematic Review of Published Cases.Dermatopathology (Basel, Switzerland) · 2025Review
- Minimally Invasive Plasma Device Management of Multiple Benign Skin Cancers Associated with Rare Genodermatoses-Case Series and Review of the Therapeutic Methods.Journal of clinical medicine · 2024Article
- Molecular and Histopathological Characterization of Metastatic Cutaneous Squamous Cell Carcinomas: A Case-Control Study.Cancers · 2024Article
- The Gray Zone of Melanocytic Tumors - A Clinical Point of View.Dermatology practical & conceptual · 2024Article
- Biologic Gray Zone of Melanocytic Tumors, Fiction or Reality?Dermatology practical & conceptual · 2024Article
- A Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.British journal of biomedical science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5th edition WHO Classification of Skin Tumors (2022) has introduced changes to nomenclature and diagnostics. Important differences are discussed below. Changes in each category of skin tumor have been detailed, with particular emphasis on meaningful advances in our understanding of the molecular pathogenesis of the skin's diverse tumor landscape.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.